In the BioHarmony Drug Report Database
Tofacitinib
Xeljanz (tofacitinib) is a small molecule pharmaceutical. Tofacitinib was first approved as Xeljanz on 2012-11-06. It is used to treat rheumatoid arthritis in the USA. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK3, tyrosine-protein kinase JAK1, and tyrosine-protein kinase JAK2. In addition, it is known to target serine/threonine-protein kinase N1 and non-receptor tyrosine-protein kinase TYK2. Xeljanz’s patents are valid until 2034-03-14 (FDA).
Trade Name
|
Xeljanz |
|---|---|
Common Name
|
tofacitinib |
ChEMBL ID
|
CHEMBL221959 |
Indication
|
rheumatoid arthritis |
Drug Class
|
Tyrosine kinase inhibitors: janus kinase inhibitors |
Image (chem structure or protein)